Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a confirmed diagnosis of a high-grade brain tumour (grade III or IV glioma, including glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, or H3K27M mutant glioma) that has continued to grow or returned after treatment with bevacizumab.
• People who have previously been treated with radiation therapy and the chemotherapy drug temozolomide — any number of prior treatments for tumour progression are acceptable.
• People who finished their combined chemotherapy and radiation treatment at least 3 months ago, or whose scans or biopsy results show the tumour is growing again.
• People aged 19 years or older.
• People whose side effects from previous treatments have mostly resolved to a mild level or better.
• People who are reasonably well and able to carry out some daily activities (confirmed with trial site using a standard health performance scale).
• People whose blood counts are at acceptable levels, showing the bone marrow is producing enough blood cells.
• People whose kidneys and liver are functioning at acceptable levels, based on blood test results.
• People who are willing to give written consent after being fully informed about the trial, its risks, and alternatives.
• Women who could become pregnant must not be pregnant or breastfeeding, and must agree to use an effective barrier method of contraception during the trial and for up to 6 months after treatment ends.
• Women who could become pregnant must have a negative pregnancy test within 7 days of starting the trial (women aged 55 or older with no menstrual period for two years, or women of any age who have had their uterus and/or both ovaries surgically removed, are not required to meet this criterion).

Who may not be able to join:

• People with a serious illness, medical condition, or organ problem that, in the doctor's opinion, could affect their safety or interfere with how the study drug works.
• People who have received immunotherapy, chemotherapy, radiation, or another experimental treatment too recently before the first dose — the required waiting period depends on the specific treatment (for example, 6 weeks for lomustine or 4 weeks for temozolomide).
• People who are currently pregnant or breastfeeding.
• People who have had severe allergic reactions to bevacizumab that could not be controlled.
• People with significant heart or blood vessel problems, including: blood pressure that remains too high despite medication, a stroke within the past 6 months, or a heart attack or severe chest pain within the past 6 months.
• People with a history of abnormal bleeding disorders or serious bleeding events within the past 4 weeks (note: people on a stable dose of blood-thinning medication for at least 2 weeks may still be considered eligible — confirm with trial site).
• People with an active wound, a wound that is not healing, an active ulcer, or an untreated bone fracture within the past 2 months.
• People with a history of a hole or tear in the digestive tract, an abdominal abscess, or an abnormal passage (fistula) in the abdomen within the past 6 months.
• People who have had a major surgery, open biopsy, or serious physical injury within the past 28 days.
• People with another significant medical condition, abnormal lab results, or a mental health condition that, in the doctor's opinion, could affect their ability to follow the trial requirements or give informed consent.

Important: Always verify eligibility with the trial site directly before applying.